ERBB2 and cancer: Much smaller sets of biomarkers associated with cancer molecular subtypes (e.g. MET and HER2-positive, or EGFR, PIK3CA and KRAS mutations) were identified by DDR as compared to biomarker sets from Best et al., which makes it more practical in blood-based cancer diagnostics and therapeutic target identification.